fibrin and Lymphoma--Non-Hodgkin

The thrombin activatable fibrinolysis inhibitor (TAFI) influences the pathways regulating fibrin formation and deposition. The enormous TAFI plasma level variability present in adults may be explained by a combination of two polymorphisms in the TAFI gene (+1542C>G; 505G>A). We aimed to correlate these two polymorphisms with plasma TAFI antigen concentrations in healthy children and pediatric oncology patients with and without venous thrombosis who were supplied with Broviac central venous catheters. Polymorphisms were detected by restriction fragment length polymorphism (RFLP) analysis of polymerase chain reaction (PCR) amplification, whereas TAFI concentration was determined using a commercial enzyme-linked immunosorbent assay (ELISA). Samples from 57 controls and 67 pediatric patients (11 venous thrombotic complications) were studied. TAFI levels in healthy children and patients were not influenced by gender or age. Compared with the 505GG carriers (wild type), 505AA carriers as well as heterozygous 505GA carriers each exhibited significantly higher TAFI antigen concentrations. In contrast, the lowest TAFI levels were detected in homozygous carriers of the +1542GG polymorphism. A combination of the genotype 505AA (homozygous carrier) and +1542CC (wild type) was present in 13 probands and resulted in the highest TAFI levels. Although in oncologic patients the risk of thrombosis was markedly increased by the heterozygous factor V 1691G>A mutation, the two TAFI polymorphisms investigated exerted no thrombogenic influence.

Topics: Age Factors; Antigens; Child; Child, Preschool; Factor V; Female; Fibrin; Histone Acetyltransferases; Humans; Infant; Leukemia; Lymphoma, Non-Hodgkin; Male; Neoplasms; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Reference Values; TATA-Binding Protein Associated Factors; Transcription Factor TFIID

Evidence of activation of coagulation was sought in serial plasma samples from 25 ABMT candidates with malignant lymphoma admitted for bone marrow harvesting: 10 females and 15 males, median age 41 years (range 27-58 years). Nineteen patients had non-Hodgkin's lymphoma (NHL) and six had Hodgkin's disease. Of those with NHL, 14 had high-grade and five low- grade disease. The plasma levels of markers of activation (prothrombin fragment 1 + 2, thrombin-antithrombin complexes, fibrinopeptide A and fibrinmonomers) increased significantly (P < 0.001) in association with harvesting. Except for fibrinopeptide A, the indicators of activation were still significantly elevated 24 h after marrow aspiration. Beta-thromboglobulin, a marker of the platelet release reaction, also increased significantly (P < 0.01). Four out of nine patients in whom a long-term central venous catheter was inserted just after marrow aspiration, developed catheter-related deep vein thrombosis, verified venographically, shortly after harvesting. These results suggest that patient with malignant lymphoma undergoing marrow harvesting develop a hypercoagulable state, and that insertion of a central intravenous catheter immediately after marrow harvesting should be avoided to prevent the development of symptomatic deep vein thrombosis.

Topics: Adult; Anticoagulants; Antithrombin III; beta-Thromboglobulin; Biomarkers; Blood Coagulation; Bone Marrow Transplantation; Catheterization, Central Venous; Circadian Rhythm; Female; Fibrin; Fibrinolysis; Fibrinopeptide A; Heparin; Hodgkin Disease; Humans; Ilium; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peptide Fragments; Peptide Hydrolases; Plasminogen Activator Inhibitor 1; Platelet Count; Premedication; Prothrombin; Sternum; Subclavian Vein; Thrombophlebitis; Transplantation, Autologous; Wounds and Injuries

To describe, using two case studies, chemotherapy drug extravasation as a consequence of fibrin sheath formation.. Journal articles, textbooks, medical records, and personal experiences.. Fibrin sheath formation around venous access devices (VADs) frequently leads to persistent withdrawal occlusion (PWO). While PWO often is easily managed with small doses of thrombolytic therapy (e.g., urokinase), it may result in a more serious complication, such as chemotherapy extravasation.. Chemotherapy should not be administered through a VAD unless a free-flowing blood return can be demonstrated.. Careful nursing assessment of all VADs is important to identify complications such as fibrin sheath formation. To rule out fibrin sheath formation, nurses must obtain catheter dye studies when fibrinolytic therapy fails to restore catheter function.

Topics: Adult; Antineoplastic Agents; Catheterization, Central Venous; Catheters, Indwelling; Child; Extravasation of Diagnostic and Therapeutic Materials; Female; Fibrin; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Retrospective Studies; Thrombolytic Therapy; Thrombosis; Urokinase-Type Plasminogen Activator

Malignant angioendotheliomatosis is a rare intravascular (angiotropic) lymphoma. Patients most often present with cutaneous or central nervous system findings. We describe three patients with malignant angioendotheliomatosis involving the skin. The initial lesions in each were tender, indurated nodules on the lower extremities, resembling inflammatory panniculitis. Skin biopsies and immunohistochemical studies from all patients confirmed intravascular B-cell lymphoma. Two patients had visceral involvement, and molecular genetics studies showed clonal immunoglobulin gene rearrangement in one. Electron microscopy in this case showed increased fibrin and atypical lymphocytes within blood vessels. Malignant angioendotheliomatosis is a monoclonal intravascular lymphoma, usually of B-cell phenotype. Occlusion of small blood vessels with lymphoid cells, fibrin, and degenerating cellular debris causes the cutaneous lesions. An excisional biopsy through the depth of subcutaneous tissue may be necessary to confirm the diagnosis of malignant angioendotheliomatosis.

Topics: Aged; Aged, 80 and over; Blood Vessels; Female; Fibrin; Gene Rearrangement; Genes, Immunoglobulin; Humans; Lymphocytes; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Microscopy, Electron; Middle Aged; Molecular Biology; Phenotype; Skin Neoplasms

We report three cases of haemolytic-uraemic syndrome following bone marrow transplantation in young males. None of them was treated with cyclosporin A. All died in renal failure. Renal histology showed the typical appearances of haemolytic-uraemic syndrome. Immunoperoxidase examination of renal biopsies showed IgM and complement in blood vessels and glomeruli of all three cases. Cytomegalovirus infection was present in two cases and probable in the third. Two cases had been infected with herpes zoster. All had episodes of graft-versus-host disease. Possible pathogenetic mechanisms are discussed.

Topics: Adolescent; Basement Membrane; Biopsy, Needle; Bone Marrow Transplantation; Child; Complement System Proteins; Cyclosporins; Fibrin; Hemolytic-Uremic Syndrome; Humans; Immunoenzyme Techniques; Immunoglobulins; Kidney; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Male; Microscopy, Electron

Topics: Adult; Aged; Chronic Disease; Disseminated Intravascular Coagulation; Factor V; Factor VII; Female; Fibrin; Fibrinogen; Gaucher Disease; Hodgkin Disease; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Organ Size; Plasminogen; Polycythemia Vera; Prothrombin Time; Spleen; Splenectomy; Splenomegaly

Topics: Adult; Aged; Disseminated Intravascular Coagulation; Fibrin; Fibrinogen; Fibrinolysis; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Myeloproliferative Disorders; Plasminogen; Trypsin Inhibitors

Topics: Acute Disease; Adenine Nucleotides; Adenosine Diphosphate; Adult; Aged; Blood Platelets; Collagen; Epinephrine; Female; Fibrin; Humans; Kaolin; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Muramidase; Platelet Adhesiveness; Remission, Spontaneous; Thrombin

Topics: Adult; Agglutination Tests; Arthritis, Rheumatoid; Blood Coagulation; Blood Coagulation Disorders; Blood Coagulation Factors; Blood Coagulation Tests; Contraceptives, Oral; Erythrocytes; False Negative Reactions; False Positive Reactions; Female; Fibrin; Fibrinogen; Fibrinolysin; Fibrinolysis; Hemagglutination Inhibition Tests; Hodgkin Disease; Humans; Immunoassay; Immunodiffusion; Kidney Diseases; Liver Cirrhosis; Lymphoma, Non-Hodgkin; Male; Methods; Middle Aged; Myocardial Infarction; Neoplasms; Plasminogen; Staphylococcus

Topics: Adolescent; Adult; Agammaglobulinemia; Aged; Albumins; Animals; Antigens; Biological Evolution; Child; Child, Preschool; Fibrin; Goats; Hodgkin Disease; Humans; Immune Sera; Immunodiffusion; Immunoglobulin G; Infant; Infant, Newborn; Leukemia, Lymphoid; Lymphocytes; Lymphoid Tissue; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Middle Aged; Proteins; Solubility; Thymoma; Thymus Gland; Transferrin

Topics: Animals; Fibrin; Fibrinogen; Lymphoma, Non-Hodgkin; Neoplasm Transplantation; Neoplasms; Rats

Topics: Animals; Antibodies; Fibrin; Immunoglobulins; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasms; Rats

Topics: Blood Cells; Fibrin; Hodgkin Disease; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasms; Sarcoma